Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University at Lombardi Cancer shared on X:

“Dr. Giulia Pasello at Rome Lung 24 discusses duration of immunotherapy for non-small cell lung carcinoma (NSCLC). CheckMate 153 showed indefinite superior to 1 year in previously treated setting. In 1L, 2 year is standard. No strong data supporting longer courses. Reminder that outcomes good when stopping for toxicity.”

Source: Stephen V Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.